Stock Screener App

Gratuito -

Installare

Drug Manufacturers - Major

85.04

0.40% -0.34

Pre-mercato: 85.55 0.51 +0.60%

Astrazeneca PLC (AZN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché AZN Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Astrazeneca PLC Borsa (AZN) Ultime notizie

AstraZeneca sets $4.5bn Virginia API plant construction in motion - Pharmaceutical Technology

Turbine and AstraZeneca partner for ADC discovery - Pharmaceutical Technology

AstraZeneca: $4.5bn investment in Virginia - MarketScreener

AstraZeneca Lifts US Plant Investment to $4.5 Billion to Boost Drug Manufacturing - MarketScreener

AstraZeneca to Invest $4.5 Billion in New US Manufacturing Facility - MarketScreener

AstraZeneca breaks ground on enormous $4.5bn Virginia manufacturing plant - BioProcess International

AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity DrugsAstraZeneca (NASDAQ:AZN) - Benzinga

AstraZeneca boosts investment in Virginia plant (AZN:NASDAQ) - Seeking Alpha

AstraZeneca to invest $4.5 billion in Virginia manufacturing facility By Investing.com - Investing.com South Africa

AstraZeneca to invest $4.5B in Virginia facility - breakingthenews.net

AstraZeneca ups investment at new Virginia facility to USD4.5 billion - MarketScreener

AstraZeneca to Boost Spending on Virginia Plant by $500 Million to $4.5 Billion - MarketScreener

AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boos - GuruFocus

AstraZeneca to increase investment & scope of Virginia manufacturing facility to $4.5 bln - MarketScreener

AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump - MarketScreener

3,600 Jobs: AstraZeneca Expands Virginia Investment to $4.5B, Adds ADC Cancer Manufacturing - Stock Titan

Turbine Launches Collaboration with Astrazeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener

What machine learning models say about AstraZeneca PLC Depositary ReceiptWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com

AstraZeneca (LSE:AZN) Developments Within FTSE 100 and FTSE 350 Healthcare - Kalkine Media

AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Dru - GuruFocus

Volume spikes in AstraZeneca PLC Depositary Receipt stock – what they meanWeekly Stock Recap & Real-Time Market Sentiment Alerts - newser.com

Algen inks $555m AstraZeneca partnership for AI-powered drug discovery - BioXconomy

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener

Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary Receipt2025 Price Action Summary & AI Driven Price Forecasts - newser.com

Will AstraZeneca PLC Depositary Receipt bounce back from current supportEarnings Risk Report & High Yield Stock Recommendations - newser.com

AstraZeneca PLC $AZN Shares Sold by Prime Capital Investment Advisors LLC - MarketBeat

AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN

AstraZeneca PLC Depositary Receipt recovery potential after sell off2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com

AstraZeneca PLC Depositary Receipt stock momentum explained2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com

Stock of the Week: Is AstraZeneca a Buy After Share Price Jump? - Morningstar Canada

Barclays Keeps AstraZeneca at Overweight, Expects 'Resilient' Q3 Results - MarketScreener

AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance

What AstraZeneca Can Teach Us About Scaling Innovation Through Ecosystem Collaboration - MarketScreener

AstraZeneca Shares Surge 14% as Investment Pause Spurs Fresh Valuation Debate - Yahoo

Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock - sharewise.com

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension - Benzinga

Another Baxdrostat Success Takes Pressure Off AstraZeneca - insights.citeline.com

AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension - MarketScreener

AstraZeneca (LSE:AZN): Exploring Valuation as Shares Move Steadily Higher - Yahoo Finance

AstraZeneca PLC $AZN Stock Holdings Lowered by Meitav Investment House Ltd. - MarketBeat

AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus

AstraZeneca Reports Positive Bax24 Trial Results for Hypertension - AskTraders.com

AstraZeneca Says Phase 3 Trial of Baxdrostat Meets Endpoint in Resistant Hypertension - MarketScreener

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

AstraZeneca reports Phase III trial success for baxdrostat in hypertension - Investing.com

AstraZeneca PLC Announces Baxdrostat Demonstrates A Statistically Significant and Highly clinically meaningful Reduction in 24-Hour Systolic Blood Pressure Compared with Placebo - MarketScreener

AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial - MarketScreener

AstraZeneca and Daiichi’s Datroway trumps chemo in first-line breast cancer - Clinical Trials Arena

D.B. Root & Company LLC Cuts Stake in AstraZeneca PLC $AZN - MarketBeat

BreakingviewsAstraZeneca’s New York shift augurs London exodus - Reuters

AstraZeneca blood pressure drug succeeds in late-stage trial - Financial Times

AstraZeneka presents results for patients with resistant hypertension - MarketScreener

AstraZeneca’s experimental hypertension drug shows promising results - Investing.com

AstraZeneca’s baxdrostat hits key goal in major blood pressure trial - Proactive financial news

AstraZeneca says baxdrostat met primary endpoint in BAX24 Ph3 trial - MarketScreener

AstraZeneca : Baxdrostat met primary endpoint in Bax24 Ph3 trial - MarketScreener

REGAstraZeneca PLCBaxdrostat met primary endpoint in Bax24 Ph3 trial - TradingView

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases - Benzinga

AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treat - GuruFocus

AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha

AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer - BioPharma Dive

AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC - insights.citeline.com

AstraZeneca signs up to $555 million AI deal with Algen to develop therapies - Reuters

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy - AOL.com

Can AstraZeneca keep on growing? - Investors' Chronicle

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters